Abraxis BioScience
Abraxis BioScience is a global biopharmaceutical company dedicated to meeting the needs of critically ill patients, with over 2000 employees worldwide.[1] Abraxis' portfolio includes the world's first protein-based nanoparticle chemotherapeutic compound called nab Technology.[2] From this the company has developed Abraxane, a treatment for metastatic breast cancer.[3] On June 30, 2010, it was announced that Abraxis BioScience would be acquired by Celgene Corporation.[4]
HIstory
Restructure of 2007
In August 2007, Abraxis announced it would undergo a restructuring to separate it's "hospital-based products business" from its "proprietary products business" into two public companies; this would involve the merging of Abraxis Oncology and Abraxis Research subunits to form a new Abraxis Bioscience (Abraxis Bioscience, Inc., NASDAQ: ABII), and the spinoff of Abraxis Pharmaceutical Products (APP, Inc., NASDAQ: APPX).[5] This reorganization was completed in November 2007.[6] During the reorganization, the new Abraxis Bioscience was known briefly as "New Abraxis".[6]
References
- ↑ BioPortfolio, 2007, "InDepth Summary", 10/11/2009[dead link]
- ↑ Abraxis BioScience, 2008, "Nab Technology", 10/11/2009
- ↑ Hoovers.[dead link]
- ↑ Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 6.0 6.1 Lua error in package.lua at line 80: module 'strict' not found.
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
